rhEGF联合玻璃酸钠滴眼液用于白内障MIOL植入术后疗效观察  

Effect of recombinant human epidermal growth factor combined with sodium hyaluronate eye drops in patients with cataract after multifocal intraocular lens implantation

作　　者：王晶[1] 高莉莉[1] 栗映梅[1] Wang Jing;Gao Lili;Li Yingmei(Refractive Surgery Center,Jinan 2nd People's Hospital,Jinan 250000,Shandong Province,China)

机构地区：[1]济南市第二人民医院屈光手术中心,济南250000

出　　处：《中国基层医药》2024年第4期487-491,共5页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的观察重组人表皮生长因子(rhEGF)联合玻璃酸钠滴眼液用于白内障患者多焦点人工晶状体(MIOL)植入术后的临床效果及对泪液中炎性因子、泪膜稳定性的影响。方法采用随机对照研究,选取济南市第二人民医院2020年7月至2023年1月行MIOL植入术的白内障患者86例为研究对象,依据随机数字表法分为对照组、联合组各43例。对照组术后予玻璃酸钠滴眼液治疗,联合组术后予rhEGF联合玻璃酸钠滴眼液治疗,两组持续给药1个月。比较两组患者治疗前后泪液中炎性因子水平、泪膜稳定性相关指标、角膜内皮细胞情况,记录治疗期间不良反应发生情况。结果治疗后,联合组泪液中白细胞介素6、肿瘤坏死因子α分别为(17.91±2.45)μg/L、(72.14±8.43)μg/L,均显著低于对照组的(24.63±3.05)μg/L、(86.97±9.85)μg/L(t=11.26、7.50,均P<0.001);联合组角膜荧光染色评分为(2.34±0.37)分,显著低于对照组的(3.42±0.48)分,泪膜破裂时间、泪液分泌试验I分别为(8.68±0.96)s、(9.31±1.04)mm/5 min,显著多于对照组的(7.81±0.89)s、(7.14±0.86)mm/5 min,两组比较,差异均有统计学意义(t=11.69、-4.36、-10.54,均P<0.001);联合组角膜内皮细胞密度、六角形细胞比例分别为(2514.09±259.31)个/mm^(2)、(41.67±5.05)%,均显著高于对照组的(2244.82±253.37)个/mm^(2)、(36.75±4.96)%(t=-4.87、-29.45,均P<0.001)。联合组不良反应发生率为11.63%(5/43),高于对照组的6.98%(3/43),但差异无统计学意义(χ^(2)=0.55,P>0.05)。结论白内障患者MIOL植入术后接受rhEGF联合玻璃酸钠滴眼液治疗可显著下调泪液中炎性因子水平,提高泪膜稳定性,促进受损角膜修复,且安全性高。Objective To investigate the clinical efficacy of recombinant human epidermal growth factor combined with sodium hyaluronate eye drops in the treatment of cataracts after multifocal intraocular lens implantation and its effect on inflammation factors in tears and tear film stability.Methods A total of 86 patients with cataracts who underwent multifocal intraocular lens implantation at Jinan 2nd People's Hospital from July 2020 to January 2023 were included in this randomized controlled study.These patients were randomly divided into a control group and a combined group,with 43 patients in each group.Patients in the control group were administered sodium hyaluronate eye drops postoperatively,while patients in the combined group received a combination of recombinant human epidermal growth factor and sodium hyaluronate eye drops.All patients were treated for 1 month.Before and after treatment,the levels of inflammatory factors in tears,tear film stability-related indicators,and corneal endothelial cells were measured and compared between the two groups.Additionally,any adverse reactions experienced by the patients were recorded throughout the treatment period.Results After treatment,the levels of interleukin-6 and tumor necrosis factor-αin the tear fluid of the combined group were(17.91±2.45)μg/L and(72.14±8.43)μg/L,respectively.These values were significantly lower than those in the control group,which were(24.63±3.05)μg/L and(86.97±9.85)μg/L,respectively(t=11.26,7.50,both P<0.001).Additionally,the fluorescein staining score for corneal damage in the combined group was(2.34±0.37)points.This was significantly lower than the score of(3.42±0.48)points observed in the control group(t=11.69,P<0.001).Tear break-up time and Schirmer I Test in the combined group were(8.68±0.96)seconds and(9.31±1.04)mm/5 minutes,respectively.These values were significantly higher than those in the control group,which were(7.81±0.89)seconds and(7.14±0.86)mm/5 minutes,respectively(t=-4.36,-10.54,both P<0.001).Furthermore,the co

关 键 词：白内障 有晶状体眼人工晶状体植入术 手术后医护 表皮生长因子 白细胞介素6 肿瘤坏死因子α 玻璃酸钠滴眼液 

分 类 号：R779.6[医药卫生—眼科]